Kojima M, Maeda M, Komatsu H, Shimoirisa H
Steroids. 1977 Apr;29(4):443-51. doi: 10.1016/0039-128x(77)90064-2.
6beta-Bromomethyl-19-norcholest-5(10)-en-3beta-ol (NCL-6-Br) was synthesized directly from cholest-5-ene-3beta,19-diol 19-toluene-p-sulfonate via homoallylic rearrangement with ammonium bromide or sodium bromide in acetonitrile. This method was applied to the radiolabeling of NCL-6-Br with bromine-82. Tissue distribution of bromine-82 labeled NCL-6-Br (NCL-6-Br-82) in rats was determined. The mean percent dose per gram uptake in adrenal at 24 and 120 h was 98 and 80 %/gm, respectively, which indicated a higher adrenal uptake as compared to iodine-131 labeled 19-iodocholest-5-en-3beta-ol (CL-19-I-131), but was at a lower level than that achieved with iodine-131 labeled 6beta-iodomethyl-19-norcholest-5(10)-en-3beta-ol (NCL-6-I-131). The ratio of radioactivity in the adrenal-to-liver concentration was also lower than that of CL-19-I-131 or NCL-6-I 131.
6β-溴甲基-19-降胆甾-5(10)-烯-3β-醇(NCL-6-Br)由胆甾-5-烯-3β,19-二醇19-对甲苯磺酸酯在乙腈中与溴化铵或溴化钠通过高烯丙基重排直接合成。该方法用于用溴-82对NCL-6-Br进行放射性标记。测定了溴-82标记的NCL-6-Br(NCL-6-Br-82)在大鼠体内的组织分布。在24小时和120小时时,肾上腺中每克摄取的平均剂量百分比分别为98%/克和80%/克,这表明与碘-131标记的19-碘胆甾-5-烯-3β-醇(CL-19-I-131)相比,肾上腺摄取更高,但低于碘-131标记的6β-碘甲基-19-降胆甾-5(10)-烯-3β-醇(NCL-6-I-131)。肾上腺与肝脏中放射性的浓度比也低于CL-19-I-131或NCL-6-I 131。